FDA classifies Alkem, Aurobindo facilities as OAI; new CEO defends Gilead’s HIV prevention drug

This week, Phispers brings you news about the FDA classifying three plants of Indian drug major Aurobindo Pharma and an Alkem Laboratories plant in the US as Official Action Indicated (OAI). Gilead’s new CEO Daniel O’Day defended&n...

FDA classifies Alkem, Aurobindo facilities as OAI; new CEO defends Gilead’s HIV prevention drug

23 May 2019

Radio Compass

PharmaCompass.com

View: 1400

Read More

New book on quality issues in generic drugs sends FDA in damage control mode; 21 generic firms sued over price-fixing

This week, Phispers is loaded with news from the US. First, a coalition of 44 states sued Teva and 20 other generic companies for price fixing.  Second, a new book titled ‘Bottle of Lies’, by investigative journalist Katherine Eba...

New book on quality issues in generic drugs sends FDA in damage control mode; 21 generic firms sued over price-fixing

16 May 2019

Radio Compass

PharmaCompass.com

View: 1460

Read More

Insys founder Kapoor convicted in opioid scandal; FDA rules changing due to new technologies

This week, Phispers brings you news about John Kapoor, the founder of Insys who was found guilty of engaging in a bribery scheme to get doctors to prescribe a highly potent and addictive opioid. FDA granted approval to Pfizer’s rare and fatal...

Insys founder Kapoor convicted in opioid scandal; FDA rules changing due to new technologies

09 May 2019

Radio Compass

PharmaCompass.com

View: 1579

Read More

EMA raises NDMA impurity concerns in diabetes drug made by Hetero; shareholder revolt rocks Bayer

This week, there is news on EMA telling companies using certain reagents to make diabetes drug — pioglitazone — to check their processes and rule out the presence of a nitrosamine impurity.  Bayer faced shareholder revolt for p...

EMA raises NDMA impurity concerns in diabetes drug made by Hetero; shareholder revolt rocks Bayer

02 May 2019

Radio Compass

PharmaCompass.com

View: 2063

Read More

Another Lupin facility gets FDA’s OAI classification; layoffs at GSK’s R&D ops; Sandoz gets new CEO

This week Phispers has news on regulatory action, a new CEO appointment, lobbying, data theft and layoffs. Another plant of Indian drugmaker Lupin received an OAI letter from the USFDA. After companies like GSK, Eli Lilly and Genentech, data...

Another Lupin facility gets FDA’s OAI classification; layoffs at GSK’s R&D ops; Sandoz gets new CEO

25 Apr 2019

Radio Compass

PharmaCompass.com

View: 1650

Read More

Top drugs and pharmaceutical companies of 2018 by revenues

The drug pricing debate continued to dominate news headlines in 2018, and many companies were in the news for lowering drug prices to make treatments more affordable. Despite that, most major pharmaceutical companies saw their sales grow in 2018.&n...

Top drugs and pharmaceutical companies of 2018 by revenues

18 Apr 2019

Radio Compass

PharmaCompass.com

View: 4156

Read More

BMS-Celgene mega-merger gets shareholder nod; 10 people die in another industrial accident in China

This week, Phispers brings you an update on the US$ 74 billion BMS-Celgene mega-merger, which was facing investor opposition. The shareholders of BMS have approved the takeover of Celgene. French drugmaker Sanofi announced an innovative model to ma...

BMS-Celgene mega-merger gets shareholder nod; 10 people die in another industrial accident in China

18 Apr 2019

Radio Compass

PharmaCompass.com

View: 711

Read More

Apotex explores sale; Perrigo looks at selling prescription business; Takeda puts Latam biz on the block

This week, Phispers has good news for patients on sartan drugs. For the first time since nitrosamine impurities were discovered last year, the USFDA released a list of BP drugs that are safe for patient use. The EU launched a WTO case against Tur...

Apotex explores sale; Perrigo looks at selling prescription business; Takeda puts Latam biz on the block

11 Apr 2019

Radio Compass

PharmaCompass.com

View: 1975

Read More

Astra strikes US$ 6.9 billion oncology deal with Daiichi; Cipla, Jubilant, Indoco’s FDA inspection updates

This week, Phispers brings you news about AstraZeneca’s US$ 6.9 billion deal with Japanese drug major Daiichi Sankyo, wherein the two will jointly develop a promising cancer therapy currently in phase III trials. Novartis acquired a portfolio...

Astra strikes US$ 6.9 billion oncology deal with Daiichi; Cipla, Jubilant, Indoco’s FDA inspection updates

04 Apr 2019

Radio Compass

PharmaCompass.com

View: 1442

Read More

US market offers niche opportunities, reveals manufacturer sales data from Medicare Part D

This week, PharmaCompass reviews the recently released data of the Medicare Part D Prescription Drug Program in the United States for calendar year 2017. The US market is the world’s largest and most important pharmaceutical market, accountin...

US market offers niche opportunities, reveals manufacturer sales data from Medicare Part D

28 Mar 2019

Radio Compass

PharmaCompass.com

View: 1273

Read More

PharmaCompass